News

IIBB researchers discover a new regulatory mechanism of STARD1 in Niemann-Pick disease type C (NPC).

 

Read More

A project with the participation of IIBB-CSIC researchers receives funding from La Marató de TV3 against COVID-19

In this year's call for La Marató de TV3 dedicated to fighting COVID-19, 229 proposals have been presented, of which 36 have been selected.

Read More

Doctor Francesc Artigas has been awarded the premi SCB Trajectòria Professional Leandre Cervera 2021

Read More

Oligonucleotide therapeutics as a new class of treatment for brain diseases

Messenger RNA (mRNA) is becoming an increasingly important target for therapeutic intervention. The mRNA molecule transmits information directly from the genome.

Read More

April 11 - World Parkinson's Disease Day at the IIBB (video)

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer’s disease and is characterized by a progressive loss of neurons involved in the control of movement.

Read More

The IIBB publishes 12 offers for JAE intro 2021 candidates

More info and details are available here.

Applications deadline: 08/04/2021

Read More

Modified oligonucleotide targets mutant alpha-synuclein forms in Parkinson's disease

  • The oligonucleotide, designed to act only on dopaminergic and noradrenergic neurons, reduces the production and accumulation of the mutant alpha-synuclein protein, a key protein in the development of Parkinson's disease

  • The work is led by the Barcelona Biomedical Research Institute of the CSIC and IDIBAPS

Read More

Pages